Navigation Links
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Date:5/27/2009

invaluable, and we can now incorporate these insights in a follow-on clinical trial that we are planning to initiate later this year. Our goal remains to significantly improve the symptoms of Parkinson's patients and also to provide the opportunity to delay further disease progression."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in October 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for a minimum of 12 months for safety and efficacy, with over half the subjects followed for 15 to 18 months under blinded conditions, allowing longer-term analyses of the therapeutic effects of CERE-120. Ceregene gratefully acknowledges the financial support received from the Michael J. Fox Foundation for Parkinson's Research to help defray some of the costs of the CERE-120 Phase 1 and Phase 2 clinical trials.

About CERE-120 and its Application to Treating Parkinson's Disease

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. Neurturin is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharm
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
2. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
5. Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
6. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
7. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
8. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
11. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... 22, 2014 Hay House is pleased to ... and Upgrade Your Life (Paperback; $10.82) written by the highly ... Recovery. This book is meant to help readers of ... of recovery. , Recovery 2.0 is not the average ... 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Losing Weight Your ... industry is staring you in the face, it certainly can ... not do your body an extra favor by doing it ... tempting crash diets. Instead, listen to your body, exercise regularly, ... Exercise is essential to losing weight; you need to exercise ...
(Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Measures taken ... plantation in Ebola-ravaged Liberia may have limited the spread ... researchers report. The Firestone Natural Rubber Co. provides ... and residents of nearby densely populated communities. Between ... and suspected Ebola cases among those 80,000 people. That ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... Arbor, Mich. Researchers have identified a gene mutation that causes ... according to U-M Medical School scientists. In the study ... Academy of Sciences USA, U-M,s Marci Lesperance, M.D., and ... examined the DNA of individuals from the same large family ...
... LA JOLLA, Calif., July 12, 2010 Some types ... to metastasize than others. Nearly one-third of these aggressive ... known as neuroendocrine-type cells. More rarely, some aggressive prostate ... The presence of neuroendocrine-type cancer cells is associated with ...
... Irvine, Calif., July 12, 2010 UC Irvine public ... research in impoverished reaches of China, Myanmar and Thailand, ... million of a seven-year, $14.5 million award to Pennsylvania ... Infectious Diseases. Yan will collaborate with Penn State principal ...
... A new Mayo Clinic study found that apathy and ... impairment (MCI), a disorder of the brain that affects ... Alzheimer,s disease and Lewy body dementia. The study was ... Honolulu on July 11, 2010. "An important ...
... to be much more complex than previously thought. In ... , Loyola University Health System researchers describe an example of ... be rare in bacteria. This discovery that protein acetylation ... a new age" in bacterial research, senior author Alan Wolfe, ...
... AIDS Society (IAS), conveners of the International AIDS Conference, ... Living with HIV (GNP+), the International Council of AIDS ... HIV/AIDS (ICW) and the United Nations Joint Programme on ... society and local partners for the XIX International AIDS ...
Cached Medicine News:Health News:U-M researchers identify gene mutation that causes rare form of deafness 2Health News:How prostate cancer packs a punch 2Health News:Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment 2Health News:'Dawning of a new age' in bacteria research 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 3
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... of influenza A and B ... to the availability of effective ... influenza using Clearview Exact Influenza ... to reduced hospital stays, antimicrobial ...
... (532 nm) is the newest,addition to ... family is widely,accepted for its reliability, ... it makes,up the worlds largest installed ... OR laser was specifically,designed for the ...
...
Medicine Products: